Postnatal corticosteroid use for prevention or treatment of bronchopulmonary dysplasia in England and Wales 2012-2019: a retrospective population cohort study
Sijia Yao,Sabita Uthaya,Chris Gale,Neena Modi,Cheryl Battersby,UK Neonatal Collaborative (UKNC),Matthew Babirecki,Anand Kamalanathan,Clare Cane,Kavi Aucharaz,Aashish Gupta,Alistair Ewing,L M Wong,Anita Mittal,Lindsay Halpern,Pinki Surana,Matt Nash,Sam Wallis,Ahmed Hassan,Karin Schwarz,Shu-Ling Chuang,Penelope Young,Ramona Onita,Graham Whincup,Joanne Dangerfield,Jocelyn Morris,Yee Aung,Abdul Hasib,Mehdi Garbash,Alex Allwood,Pauline Adiotomre,Nigel Brooke,Abby Deketelaere,Toria Klutse,Sonia Spathis,Sathish Krishnan,Samar Sen,Jez Jones,Geedi Farah,Prem Pitchaikani,Jennifer Holman,Stanley Zengeya,Geraint Lee,Sobia Balal,Cath Seagrave,Tristan Bate,Hilary Dixon,Narendra Aladangady,Hassan Gaili,Matthew James,M Lal,Oluseun Tayo,Poornima Pandey,Ravindra Bhat,Simon Rhodes,Jonathan Filkin,Savi Sivashankar,Lawrence Miall,Jonathan Cusack,Venkatesh Kairamkonda,Michael Grosdenier,Ajay Reddy,J Kefas,Alison Bedford Russell,Jennifer Birch,Gail Whitehead,Ashok Karupaiah,Ghada Ramadan,I Misra,Nicola Johnson,Richard Heaver,Mohammad Alam,Prakash Thiagarajan,Priya Muthukumar,Tiziana Fragapane,Ngozi Edi-Osagie,Cheentan Singh,Subodh Gupta,Jess Reynolds,Khadija Ben-Sasi,Steven Wardle,Victoria Nesbitt,Eleri Adams,Katharine McDevitt,Ruchika Gupta,David Gibson,Minesh Khashu,Iyad Al-Muzaffar,Kate Creese,Chinnappa Reddy,Mark Johnson,Prashanth Bhat,Patricia Cowley,Rashmi Gandhi,Charlotte Groves,Lidia Tyszcuzk,Shilpa Ramesh,Glynis Rewitzky,Julia Croft,Bushra Abdul-Malik,Dominic Muogbo,Ambalika Das,Angela D'Amore,Soma Sengupta,Christos Zipitis,Peter De Halpert,Archana Mishra,Chris Warren,John McIntyre,Nagendra Venkata,Lucinda Winckworth,Joanne Fedee,Anitha Vayalakkad,Raju Narasimhan,Lee Abbott,Ben Obi,Stephen Jones,Richard Hearn,Anjali Petkar,Jim Baird,Kirsten Mack,Arun Ramachandran,Vineet Gupta,Faith Emery,Charlotte Huddy,Salim Yasin,Akinsola Ogundiya,Pamela Cairns,Vennila Ponnusamy,Victoria Sharp,Carrie Heal,Sanjay Salgia,Imran Ahmed,Jacqeline Birch,Sunil Reddy,Porus Bastani,Marice Theron,Divyen Shah,Siba Paul,Se-Yeon Park,Giles Kendall,Puneet Nath,Hari Kumar,Nitin Goel,Chris Rawlingson,Delyth Webb,Sue Bird,Sankara Narayanan,Elizabeth Eyre,Jageer Mohammed,Sanjay Jaisal,Caroline Sullivan,Ros Garr,Wynne Leith,Vimal Vasu,Anna Gregory,Katia Vamvakiti,Brendan Harrington,Megan Eaton,Sundeep Sandhu,Michael Cronin
DOI: https://doi.org/10.1136/bmjopen-2022-063835
IF: 3.006
2022-11-17
BMJ Open
Abstract:Objective: Describe the population of babies who do and do not receive postnatal corticosteroids for prevention or treatment of bronchopulmonary dysplasia (BPD). Design: Retrospective cohort study using data held in the National Neonatal Research Database. Setting: National Health Service neonatal units in England and Wales. Patients: Babies born less than 32 weeks gestation and admitted to neonatal units from 1 January 2012 to 31 December 2019. Main outcomes: Proportion of babies given postnatal corticosteroid; type of corticosteroid; age at initiation and duration, trends over time. Secondary outcomes: Survival to discharge, treatment for retinopathy of prematurity, BPD, brain injury, severe necrotising enterocolitis, gastrointestinal perforation. Results: 8% (4713/62019) of babies born <32 weeks and 26% (3525/13527) born <27 weeks received postnatal corticosteroids for BPD. Dexamethasone was predominantly used 5.3% (3309/62019), followed by late hydrocortisone 1.5%, inhaled budesonide 1.5%. prednisolone 0.8%, early hydrocortisone 0.3% and methylprednisolone 0.05%. Dexamethasone use increased over time (2012: 4.5 vs 2019: 5.8%, p=0.04). Median postnatal age of initiation of corticosteroid course was around 3 weeks for late hydrocortisone, 4 weeks for dexamethasone, 6 weeks for inhaled budesonide, 12 weeks for prednisolone and 16 weeks for methylprednisolone. Babies who received postnatal corticosteroids were born more prematurely, had a higher incidence of comorbidities and a longer length of stay. Conclusions: In England and Wales, around 1 in 12 babies born less than 32 weeks and 1 in 4 born less than 27 weeks receive postnatal corticosteroids to prevent or treat BPD. Given the lack of convincing evidence of efficacy, challenges of recruiting to and length of time taken to conduct randomised controlled trial, our data highlight the need to monitor long-term outcomes in children who received neonatal postnatal corticosteroids.